Atrial fibrillation (AF) represents the arrhythmia of greatest clinical impact and catheter ablation of atrial fibrillation (CAAF) has become the most effective strategy for rhythm control in selected patients. Therefore, appropriate anticoagulation strategies are of paramount importance for patients undergoing CAAF, especially those at high risk, such those with high CHA2DS2VASc scores. Optimal management of anticoagulation before, during, and after CAAF is crucial. Several studies have evaluated the use of different anticoagulation strategies in the periprocedural period. Randomized controlled trial (RCTs) seem to suggest that in patients undergoing CAAF, uninterrupted (or minimally interrupted) DOACs provides an alternative to continuous-VKA strategy, with low thromboembolic and bleeding risk.

心房颤动（AF）代表最大的临床影响的心律失常，而心房纤颤（CAAF）的导管消融已成为所选患者节律控制的最有效策略。因此，对于正在接受CAAF的患者，尤其是高风险患者，例如CHA2DS2VASc评分高的患者，适当的抗凝策略至关重要。CAAF之前，期间和之后的最佳抗凝管理至关重要。数项研究评估了围手术期不同抗凝策略的使用。随机对照试验（RCT）似乎表明，在接受CAAF的患者中，不间断（或最小程度间断）的DOAC可替代连续VKA策略，具有较低的血栓栓塞和出血风险。